{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "Amount",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "uaz:UAZ02749",
      "entity_text" : "lambda and kappa FLC",
      "entity_type" : "protein"
    },
    "hypothesis_information" : false,
    "context" : {
      "TissueType" : [ "tissuelist:TS-0672" ],
      "CellLine" : [ "cellosaurus:CVCL_E829" ],
      "Organ" : [ "uberon:UBERON:0002384" ],
      "Species" : [ "taxonomy:9606" ],
      "CellType" : [ "cl:CL:0000786" ]
    }
  },
  "verbose_text" : "Aggarwal et al [XREF_BIBR] reported higher levels of both lambda and kappa FLC in patients with SLE or RA than in normal controls, and that testing for FLC in addition to testing C3, C4, and anti-ds-DNA antibody levels is useful for assessing disease activity in SLE.",
  "reading_complete" : "2020-07-28T18:29:53Z",
  "reader_type" : "machine",
  "reading_started" : "2020-07-28T18:27:17Z",
  "trigger" : "levels",
  "evidence" : [ "levels of both lambda and kappa FLC" ],
  "pmc_id" : "5662307",
  "score" : 0
}